About ConcePTION

ConcePTION is a project funded by the Innovative Medicines Initiative, a private public partnership. The project was launched in April 2019.

We believe that we have an important societal obligation to radically and rapidly reduce uncertainty about the effects of medication used during pregnancy and breastfeeding to benefit women in making informed decisions about medications used before, during and after pregnancy.

Reporting medicine use in pregnancy

Did you use any medicines when you were pregnant? Here is how you and your health care provider can report what we call an exposure.

Ten principles for stakeholder engagement in the ConcePTION project

The ConcePTION project is building much-needed knowledge for women and health care professionals. To achieve our goal of building an ecosystem for medicine safety in pregnancy and breastfeeding, we need to engage with women, their partners, their doctors, pharmacists, midwives and nurses, the companies that develop medicines and the authorities that approve them and decide what becomes available to patients. Our goal is to work in an open and inclusive way, with the spirit of mutual respect and trust. Here is how we engage with stakeholders in an ethical way.


Multiple Sclerosis, often referred to as MS, is an unpredictable disease that affects the central nervous system. The disease can debut at any age, but most often manifests between the ages of 20 and 40 and women are more at risk. Certain forms of MS respond well to a drug called dimethyl fumarate. Because we don’t know enough about how this drug transfers to breastmilk, new mothers who are on this medication often face difficult decisions about breastfeeding. A recent case report published in Frontiers in Public Health shares findings that help fill this knowledge gap – towards a future where women can make informed decisions.  | READ MORE >>
Since the launch in 2019, 80 partners representing key stakeholders in the field have worked together to build an ecosystem that can empower pregnant and breastfeeding women to make informed decisions about medicines. On June 13-14, The IMI ConcePTION consortium convened one last time at the historic De Bazel building in Amsterdam to reflect on the advancements and make plans for the last six months of the project.  | READ MORE >>
A recent paper published by researchers involved in the ConcePTION project explores the complexities of health information collected in electronic databases, commonly used to study the safety and effectiveness of medicines. Understanding the diverse features of these data sources is crucial for researchers to reproduce studies and validate their results. Something that can help us fill the knowledge gap on medicine safety in pregnancy and breastfeeding.  | READ MORE >>

Twitter / X

the availability of physiological data in infants for PBPK modelling can be improved by systematic searches, as the physiology of a breastfed is different from a formula fed infant. Relevant for lactation-related drug exposure. https://www.mdpi.com/1999-4923/15/11/2618. IMI Conception.

JUST PUBLISHED: Challenges Related to Acquisition of Physiological Data for Physiologically Based Pharmacokinetic (PBPK) Models in Postpartum, Lactating Women and Breastfed Infants—A Contribution from the ConcePTION Project 👇

Connect with us!

The ConcePTION consortium

The project unites an unprecedented 88 organizations from 22 countries, including the European Medicines Agency, drug manufacturers, academia, public health organizations, and teratology networks to innovate new solutions to a decades-long public health issue.


The ConcePTION project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 821520. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.